MedTrace Logo

Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

NCT00842023 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2013-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

Nesiritide

Bolus 2 mcg/kg followed by 0.01 mcg/kg/min

DRUG

Nitroglycerin

5-10 mcg/min titrating per protocol based on blood pressure

Sponsors & Collaborators

  • American College of Clinical Pharmacy

    collaborator OTHER

  • Western University of Health Sciences

    lead OTHER

Principal Investigators

  • Sheryl L. Chow, PharmD, FCCP, BCPS · Western University of Heatlh Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-07-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842023 on ClinicalTrials.gov